Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements
The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market.
LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the Cushing's Disease Market Report
According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024.
In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US.
Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034).
Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years.
The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others.
In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism.
In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026.
In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome.
Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report
Cushing's Disease Overview
Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies.
Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years.
Cushing's Disease Epidemiology Segmentation
The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalent Cases of Cushing's Disease
Total Diagnosed Prevalent Cases of Cushing's Disease
Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease
Age-Specific Diagnosed Prevalent Cases of Cushing's Disease
Cushing's Disease Treatment Market
The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels.
Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include SIGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma.
SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route.
Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900).
RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action.
To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management
Cushing's Disease Pipeline Therapies and Key Companies
Relacorilant (CORT125134): Corcept Therapeutics
Clofutriben (SPI-62): Sparrow Pharmaceuticals
Atumelnant (CRN04894): Crinetics Pharmaceuticals
Lu AG13909: H. Lundbeck
ST-002: Stero Therapeutics
Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials
Cushing's Disease Market Dynamics
The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR.
Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM.
However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies.
Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth.
Cushing's Disease Market Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].
Cushing's Disease Market Size in 2024
USD 1 Billion
Key Cushing's Disease Companies
Xeris Pharmaceuticals, Recordati, Corcept Therapeutics, Sparrow Pharmaceuticals, H. Lundbeck, Stero Therapeutics, Crinetics Pharmaceuticals, and others
Key Cushing's Disease Therapies
RECORLEV, ISTURISA, SIGNIFOR, SIGNIFOR LAR, KORLYM, Relacorilant, Clofutriben, Lu AG13909, ST-002, Atumelnant, and others
Scope of the Cushing's Disease Market Report
Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies
Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement
Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Cushing's Disease Market Overview at a Glance
6.1
Market Share (%) Distribution by Therapies of Cushing's Disease in 2024
6.2
Market Share (%) Distribution by Therapies of Cushing's Disease in 2034
7
Disease Background and Overview
7.1
Introduction
7.2
Clinical and Biological Characteristics
7.3
Genetics of Cushing's Disease
7.4
Pathogenesis and Pathophysiology
7.5
Complications of Cushing's Disease
7.6
Diagnosis of Cushing's Disease
7.6.1
Diagnostic Algorithm
7.7
Treatment and Management of Cushing's Disease
7.7.1
Treatment Algorithm of Cushing's Disease
8
Guidelines, Recommendations, and Management for Cushing's Disease
8.1
Consensus on Diagnosis and Management of Cushing's Disease: A Guideline Update (2020) (The United States)
8.2
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline (2015) (Europe)
8.3
Clinical Significance of Screening for Subclinical Cushing's Disease in Patients With Pituitary Tumors (2010) (Japan)
9
Epidemiology and Patient Population
9.1
Key Findings
9.2
Assumptions and Rationales
9.3
Total Diagnosed Prevalent Cases of Cushing's Disease in the 7MM
9.4
The United States
9.4.1
Total Diagnosed Prevalent Cases of Cushing's Disease in the US
9.4.2
Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in the US
9.4.3
Age-specific Diagnosed Prevalent Cases of Cushing's Disease in the US
9.5
EU4 and the UK
9.5.1
Total Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK
9.5.2
Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK
9.5.3
Age-specific Diagnosed Prevalent Cases of Cushing's Disease in EU4 and the UK
9.6
Japan
9.6.1
Total Diagnosed Prevalent Cases of Cushing's Disease in Japan
9.6.2
Gender-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan
9.6.3
Age-specific Diagnosed Prevalent Cases of Cushing's Disease in Japan
10
Patient Journey
11
Marketed Drug
11.1
Marketed Drug Details
11.2
ISTURISA (osilodrostat): Recordati
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Clinical Development Activities
11.2.4.1
Clinical Trials Information
11.2.5
Safety and Efficacy
11.3
RECORLEV (levoketoconazole): Xeris Pharmaceuticals
11.3.1
Product Description
11.3.2
Regulatory Milestones
11.3.3
Other Developmental Activities
11.3.4
Safety and Efficacy
11.4
SIGNIFOR (pasireotide): Recordati
11.4.1
Product Description
11.4.2
Regulatory Milestones
11.4.3
Other Developmental Activities
11.4.4
Safety and Efficacy
11.5
SIGNIFOR LAR (pasireotide pamoate): Recordati
11.5.1
Product Description
11.5.2
Regulatory Milestones
11.5.3
Other Developmental Activities
11.5.4
Safety and Efficacy
12
Emerging Drugs
12.1
Key Cross Competition
12.2
Relacorilant (CORT125134): Corcept Therapeutics
12.2.1
Product Description
12.2.2
Other Development Activity
12.2.3
Clinical Development
12.2.3.1
Clinical Trial Information
12.2.4
Safety and Efficacy
12.3
Clofutriben (SPI-62): Sparrow Pharmaceuticals
12.3.1
Product Description
12.3.2
Other Development Activity
12.3.3
Clinical Development
12.3.3.1
Clinical Trial Information
12.3.4
Safety and Efficacy
12.4
Atumelnant (CRN04894): Crinetics Pharmaceuticals
12.4.1
Product Description
12.4.2
Other Development Activity
12.4.3
Clinical Development
12.4.3.1
Clinical Trial Information
12.4.4
Safety and Efficacy
13
Cushing's Disease: Seven Major Market Analysis
13.1
Key Findings
13.2
Market Outlook
13.3
Key Market Forecast Assumptions
13.3.1
Cost Assumptions and Rebates
13.3.2
Pricing Trends
13.3.3
Analogue Assessment
13.3.4
Launch Year and Therapy Uptakes
13.4
Conjoint Analysis
13.5
Total Market Size of Cushing's Disease in the 7MM
13.6
Market Size of Cushing's Disease by Therapies in 7MM
13.7
The United States
13.7.1
Total Market Size of Cushing's Disease in the US
13.7.2
Market Size of Cushing's Disease by Therapies in the US
13.8
EU4 and the UK
13.8.1
Total Market Size of Cushing's Disease in the EU4 and the UK
13.8.2
Market Size of Cushing's Disease by Therapies in EU4 and the UK
13.9
Japan
13.9.1
Total Market Size of Cushing's Disease in Japan
13.9.2
The Market Size of Cushing's Disease by Therapies in Japan
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Market Access and Reimbursement
17.1
The United States
17.1.1
Centre for Medicare and Medicaid Services (CMS)
17.2
EU4 and the UK
17.2.1
Germany
17.2.2
France
17.2.3
Italy
17.2.4
Spain
17.2.5
United Kingdom
17.3
Japan
17.3.1
MHLW
17.4
Market Access and Reimbursement of Cushing's Disease
18
Appendix
18.1
Bibliography
18.2
Report Methodology
19
DelveInsight Capabilities
20
Disclaimer
21
About DelveInsight
Related Reports
Cushing's Syndrome Market
Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others.
Cushing's Syndrome Pipeline
Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others.
Endogenous Cushing's Syndrome Market
Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others.
Endogenous Cushing's Syndrome Pipeline
Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur info@delveinsight.com +14699457679www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/cushings-disease-market-poised-for-significant-growth-across-the-7mm-during-the-study-period-20202034-with-rising-awareness-and-diagnostic-improvements--delveinsight-302456270.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
a day ago
- Gizmodo
Four Democrat-Led States Ask FDA to Lift Restrictions on Abortion Pill
The attorneys general of four Democrat-led states—New York, New Jersey, Massachusetts, and California—petitioned the Food and Drug Administration on Thursday, June 5, asking the agency to lift what they view as unnecessary restrictions on the abortion pill mifepristone. The petition aims to force the FDA to acknowledge robust clinical evidence and decades of mifepristone use that support the drug's safety and efficacy. The move comes just one month after Health and Human Services Secretary Robert F. Kennedy Jr. told Congress that he ordered a safety review of the abortion pill. An FDA spokesperson confirmed plans for the review in a statement to CBS News on Tuesday, June 3. According to the FDA, mifepristone, approved by the regulator in 2000, is a drug that blocks the hormone progesterone, which is necessary for pregnancy to continue. It is most commonly used in combination with the drug misoprostol to terminate a pregnancy within 10 weeks of gestation. An analysis of 2023 data by the Guttmacher Institute found that medication abortions account for more than half (63%) of all abortions in the U.S. But in the years since the Supreme Court overturned Roe v. Wade, 17 states have banned this medication, and an additional 10 states have placed restrictions on it, according to the Washington Post. 'The medication is a lifeline for millions of women who need access to time-sensitive, critical healthcare—especially low-income women and those who live in rural and underserved areas,' California attorney general Rob Bonta told the Los Angeles Times. The petition specifically asks the FDA to lift the mifepristone Risk Evaluation and Mitigation Strategy (REMS) Program. This additional regulatory framework is designed to 'help ensure the benefits of the medication outweigh its risks,' according to the FDA. REMS has been applied to 325 medications since its inception and currently applies to 71 drugs. REMS places multiple restrictions on mifepristone use, including that prescribers be put on national and local abortion provider lists; patients give written statements that they intend to end their pregnancies; and pharmacies keep records of mifepristone prescribers and users. The attorneys general argue that these rules 'impose unnecessary and burdensome hurdles on patients, prescribers, pharmacists, and the healthcare system.' They also point out that mifepristone has been marketed in the U.S. for decades and has been safely used by more than 7.5 million American women. 'Moreover, no new evidence raising safety concerns has emerged in the last two decades,' they state. These states are not alone in their pursuit of expanded mifepristone access. Seventeen other Democratic-led or -leaning states, plus Washington D.C., are suing the FDA in Spokane, Washington, to loosen restrictions on the drug, Reuters reported in February. What's more, leading medical organizations have called on the FDA to remove REMS restrictions on mifepristone for years. If the FDA declines to remove REMS, Thursday's petition asks the agency to 'exercise its discretion not to enforce' some or all of the restrictions in New York, New Jersey, Massachusetts, and California, as these states already place 'rigorous restrictions' around the practice of medicine.
Yahoo
a day ago
- Yahoo
Confusion over maternal care medication plagues politics in Louisiana and beyond
Packages of Mifepristone tablets are displayed at a family planning clinic on April 13, 2023, in Rockville, Maryland. (Photo illustration by) A year ago, Gov. Jeff Landry signed a bill into law that made Louisiana the first state in the country to reclassify pregnancy care drugs as controlled dangerous substances. Since then, the political assault on the medications has continued to ramp up on the state and national level. The Louisiana law to reclassify mifepristone and misoprostol caused controversy, particularly when multiple medical professionals publicly criticized the measure saying the added burdens to accessing the medications could delay medical treatment in times of crisis. Misoprostol and mifepristone have been targeted because they are used in medication abortion, but both have multiple other uses. Misoprostol is used to prevent and treat postpartum hemorrhage. Since the state law went into effect in October, hospitals have changed how they store and dispense the drugs, locking them up in passcode-protected storage containers outside of labor and delivery rooms. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX The New Orleans Health Department has been tracking complaints from health care providers and patients who have struggled with misoprostol access since October. The medical professionals and patients were provided anonymity to encourage feedback. One doctor wrote they had trouble accessing the drug to provide to a patient going through a hysteroscopy, a medical procedure in which the doctor examines a woman's uterus using a thin, lighted tube. 'I was unable to get misoprostol in pre-op for [a] patient undergoing hysteroscope,' the provider wrote. 'Therefore [I] had to manually dilate [the] cervix multiple times causing unnecessary harm to the patient.' Another doctor said they couldn't complete a biopsy, so they prescribed misoprostol to a patient in order to try the procedure again after softening her cervix. The doctor included the patient's diagnosis of abnormal bleeding on the prescription, and that the patient was not pregnant. The pharmacy refused to fill the prescription until the doctor got on the phone to confirm the medication was not being used to end a pregnancy. 'This could lead to a delay in diagnosis of cancer,' the doctor wrote. In another instance, a pharmacist refused to fill a prescription for misoprostol ahead of an IUD insertion, telling the patient 'he thought she was going to use it for an abortion,' wrote the doctor. There were also multiple accounts of misoprostol being prescribed for miscarriages, but pharmacists delayed filling prescriptions until they spoke to the doctor on the phone. In one instance, the mother who miscarried filed a complaint with the city health department. 'I was denied misoprostol, essentially leaving me with my dead baby inside of me even longer because the pharmacist said he couldn't give it to me,' the mother wrote. 'It was more horrific than it needed to be.' Even among state lawmakers who approved the law, confusion reigns. At a Louisiana House committee hearing last month, Rep. Lauren Ventrella, R-Greenwell Springs, said that last year 'we made it illegal to prescribe' mifepristone and misoprostol. However, both can still be legally prescribed by health care providers with the proper licensing for Schedule IV drugs. When the law reclassifying the medication passed, its supporters repeatedly stated they were not restricting access to the medication for people who needed it for reasons outside of abortion. When Ventrella misspoke, she was introducing House Bill 575, which would allow families to sue over suspected abortions. Attorney General Liz Murrill has referred to the law as 'another tool in the toolbox' that could be used against out-of-state doctors who prescribe abortion medication to patients in Louisiana. Murrill is currently prosecuting at least two cases involving a New York doctor who allegedly prescribed medications to pregnant women in Louisiana. So far, New York's shield laws, which protects abortion providers, have held up against states that have tried to prosecute doctors. Ventrella's bill awaits Senate floor action with less than a week remaining in the legislative session. Opponents of the reclassification of mifepristone and misoprostol have worried that, by labeling the drugs as controlled dangerous substances, it would confuse medical providers and the public as well as stigmatize medications that have been proven to be safe and effective. They are challenging the law, Act 246, in state court, and a judge ruled May 15 that the plaintiffs suing the state have a right to pursue their case. 'Specifically, the judge agreed that the plaintiffs have sufficiently demonstrated the harm that the law is causing to their practice, and the patients that they serve, to be able to challenge the constitutionality of this law,' said Ellie Schilling, a New Orleans attorney representing the plaintiffs. The plaintiffs include the reproductive health advocacy group Lift Louisiana, the Birthmark Doula Collective and multiple women's health advocates and Louisiana health care providers, including OB-GYNs, midwives and pharmacists. As the court fight plays out in Louisiana, another clash is occurring on the national stage. U.S. Health Secretary Robert F. Kennedy Jr. has ordered the Food and Drug Administration to conduct a 'complete review' on misoprostol and mifepristone. It comes in the wake of a far-right organization publishing a paper — one that is not peer-reviewed and many critics view as unscientific — claiming the drugs cause adverse medical effects. The far-right think tank, the Ethics and Public Policy Center, claimed almost 11% of women experienced a 'serious adverse event' from the medications, but peer-reviewed clinical studies have shown an overall 0.5% rate of serious adverse events. Other research in the report also doesn't hold up to fact-checking, and its authors did not reveal where they sourced the data that was cited. 'It's deeply troubling that Secretary Kennedy is elevating junk-science to justify reopening mifepristone's safety review, especially at the behest of anti-abortion political operatives,' said Dr. Angel Foster, co-founder of the Massachusetts Abortion Access Project, which provides medication abortion care to all 50 states via telemedicine. 'I know firsthand that mifepristone's safety is backed by decades of rigorous data. Rolling back access to mifepristone would be a disaster.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
2 days ago
- Yahoo
Blue states call on FDA to expand abortion pill access
Attorneys general of New York, California, New Jersey and Massachusetts are asking the Food and Drug Administration (FDA) to expand access to the abortion pill and remove some 'unnecessary' drug restrictions that have been in place for more than two decades. The joint petition, filed Thursday, comes days after FDA Commissioner Marty Makary committed to reviewing the abortion drug amid pressure from Department of Health and Human Services Secretary Robert F. Kennedy Jr. and some Republican lawmakers. The FDA first approved of the use of mifepristone and misoprostol for an abortion in 2000. Unlike surgical abortions, medication abortions do not need to take place in a clinical setting, and patients are able to take the pills at home. Most abortions in the U.S. are now medication abortions, according to data from the reproductive health and rights group Guttmacher Institute. In 2023, 63 percent of all abortions in the U.S. were medication abortions. The safety of mifepristone has come under increased scrutiny by some Republican lawmakers, citing a flawed study claiming the rate of adverse health events that occur among patients is far higher than previously reported. More than 100 scientific studies have been conducted looking at the safety and efficacy of mifepristone and misoprostol; all of them have found that the drugs are a safe way to terminate a pregnancy. 'Given Mifepristone's 25-year safety record, there is simply no scientific or medical reason to subject it to such extraordinary restrictions,' New York Attorney General Letitia James said. 'The FDA must follow the science and lift these unnecessary barriers that put patients at risk and push providers out of care.' Mifepristone's use is subject to a Risk Evaluation and Mitigation Strategy (REMS) program under the FDA. The attorneys general argue three requirements under the REMS program for the drug should be removed since they pose a burden to patients and health care systems. The first is related to prescriber certification. As part of the REMS program, health care providers who prescribe mifepristone are required to add their names to national and abortion provider lists, which the attorneys general say raise 'serious safety and legal concerns.' The second has to do with patient agreement forms. All patients who want mifepristone — even those using the drug to treat a miscarriage — are required to sign a document stating they are using the drug to end a pregnancy. The third requirement mentioned in the petition is connected to pharmacy certification. As part of mifepristone's REMS program, pharmacies that carry the drug are subject to tracking, shipping and reporting requirements, which the attorneys general argue may 'dissuade' some from carrying the drug. The FDA has yet to reply to a request for comment from The Hill about the petition. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
